L608 Inhalation not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo”In the company’s words, NCT05938946 on ClinicalTrials.gov
- Tested for
- Pulmonary Arterial Hypertension
- Main trialPhase 1
- “This is a Phase I, randomized, double-blinded, placebo-controlled single ascending dose, sequential-group study to evaluate the safety, tolerability, and PK of single ascending doses of L608 inhalation in healthy volunteers.”In the company’s words, NCT05938946 on ClinicalTrials.gov
Other drugs for Pulmonary Arterial Hypertension
- RalinepagUnited Therapeutics · Phase 3
- SeralutinibGB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · Phase 3
- Treprostinil PalmitilInsmed Incorporated · Phase 3
- MacitentanActelion · Phase 3
- Macitentan/Tadalafil FDCActelion · Phase 3
- SelexipagActelion · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 2 Sep 2024 | Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026